drugset / Trial / NCT04224337
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.
Timeline
- Start
- 2020-06-11
- Primary completion
- 2023-08-14
- Completion
- 2025-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |
| Background | Ifosfamide | Small molecule | 1.5 g | Intravenous |